e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
61.30
-0.30 (-0.49%)
Official Closing Price
Updated: 4:10 PM EST, Feb 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
13,500,270
Open
61.50
Bid (Size)
61.24 (100)
Ask (Size)
61.47 (600)
Prev. Close
61.60
Today's Range
60.91 - 62.12
52wk Range
42.52 - 63.33
Shares Outstanding
2,222,113,553
Dividend Yield
4.11%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
February 23, 2026
Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 22.8%. Its stock price has climbed to $61.33, representing a healthy 30.1% increase. This was partly due to...
Via
StockStory
Topics
Stocks
Performance
YTD
+14.7%
+14.7%
1 Month
+12.3%
+12.3%
3 Month
+25.0%
+25.0%
6 Month
+29.8%
+29.8%
1 Year
+5.9%
+5.9%
More News
Read More
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
From
Bristol Myers Squibb
Via
Business Wire
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
February 23, 2026
Via
MarketMinute
Topics
Intellectual Property
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors
↗
February 18, 2026
Via
Chartmill
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
February 23, 2026
From
Bristol Myers Squibb
Via
Business Wire
2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm
February 22, 2026
Via
StockStory
Down 25%, Should You Buy the Dip on Bristol Myers Squibb?
↗
February 21, 2026
Via
The Motley Fool
Topics
Intellectual Property
2 Incredibly Cheap Dividend Stocks to Buy Now
↗
February 19, 2026
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook
↗
February 05, 2026
Via
Chartmill
3 Stocks to Buy and Hold for 2026 and Beyond
↗
February 19, 2026
Via
The Motley Fool
Topics
Economy
Intellectual Property
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
February 19, 2026
Via
MarketMinute
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
Via
Finterra
Topics
Lawsuit
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
February 17, 2026
From
Bristol Myers Squibb
Via
Business Wire
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
February 16, 2026
Via
MarketMinute
Topics
Intellectual Property
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
February 12, 2026
Via
StockStory
Topics
Earnings
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
February 10, 2026
Via
Finterra
Topics
Economy
Intellectual Property
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
February 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus
February 06, 2026
Via
StockStory
Why Bristol Myers Squibb Stock Topped the Market Today
↗
February 05, 2026
Via
The Motley Fool
Bristol Myers (BMY) Q4 2025 Earnings Transcript
↗
February 05, 2026
Via
The Motley Fool
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
February 05, 2026
Via
StockStory
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
February 05, 2026
From
Bristol Myers Squibb
Via
Business Wire
Frequently Asked Questions
Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 61.30
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 02/25/26 04:10 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 136.22B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 136B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert